We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.105 | 2.26% | 4.755 | 4.52 | 4.99 | - | 189,060 | 16:35:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.36M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/6/2020 10:34 | 17p!!!News cycle could have an impact. However we'll get results here which will most likely determine which way this goes. Poor first read out and it will be done for the time being regardless of the good sets of data that follow.Looking at the report posted today the nebulised version is meant to be more effective than the injection. If the hospital trial shows data anywhere close to those numbers in terms of discharge and reduced mortality then you will see this go up. I don't disagree there are numerous challenges to get to market but the move in price won't factor that immediately. Have you seen the price on some of these testing companies? lol. | sainvestor | |
01/6/2020 10:25 | I think it's a mistake to assume Lansdowne will be selling down to zero. That's not their normal MO. They will have taken profits and reduced exposure but that's very different from being out. With a market cap of around £50m, these could re-rate very quickly on any further good news about INFA as a treatment option. When Gilead released the initial results from Remdisavir, ignoring the Chinese data that suggested it didn't work, their market cap increased by close to $1bn. From my reading, INFA treatment looks at least as good, if not better given the much lower adverse events profile. | waterloo01 | |
01/6/2020 10:22 | i dont think R has much to do with business dealings here, | spartan attack | |
01/6/2020 10:21 | Marie is back! You are talking a lot of sense. I agree that the R number is bound to go up and from a scientific point of view the easing of the lock down has been a shambles. They have changed so many things at once when the inevitable happens, we won't know which of the changes caused it. As a scientist I am just sitting here with my head in my hands. | nobbygnome | |
01/6/2020 10:20 | LANDSOWNE hold 17,468,735 shares with the last file date being 6th May when they sold 1,596,604 shares. Link are the largest holder with 21,341,293 shares. This data is from my bloomberg. | markinvestor | |
01/6/2020 10:20 | Yes in most instances, short term 17/20 unrealistic in norm circ. But The forced seller does change it a bit i think | spartan attack | |
01/6/2020 10:19 | tburns, the last update was 11/05/20 when they had sold down from 12.76% to 11.69%. Thought that they had to notify as certain levels were crossed? Or is it that they can can put in an order to sell remaining 11.69% and only need to notify when order is satisfied? | hairballradical | |
01/6/2020 10:18 | SA, 17P or even 30P very unrealistic in short term. Can't see even 35P before read out. Remember, 2nd wave news and this will spike. And we all know 2nd wave is inevitable... | idontflykathyy | |
01/6/2020 10:16 | So a balancing act for Lansdowne to sell whatever they got left before the price reaches 35. | ramridge | |
01/6/2020 10:16 | The months of April and May, saw a net distribution in total volume for the two months, of approx 6,2 million weighted, in a total volume circa 12.5 million or something like that IF its correct that they need to offload, liquidity is doing them no favours. They will not get to offload all by 35p So it depends on where they commenced. And the bottom line price for a profit average. In my estimation, selling down to 26.5p will be ok for them i guess. But they probably have a 3rd party shorting it as they distribute to cover lack of liquidity All in all, i dont see 31p being supported. This will also force out retail buyers and smaller hold institutions/funds SO your looking at sub 20p with ease imo, circa 17p, to start assessing it again | spartan attack | |
01/6/2020 10:11 | I can't believe that sub 40p looks like it is coming into view. How many shares did they last have declared on their TR1, hopefully nearly out soon | tburns | |
01/6/2020 10:09 | ram, there should be TR1 then. Lansdowne overall are in deep red thanks to other exposure so guess they want to cover by selling here. They still up from their 35P purchase. As i write - dropping more.... | idontflykathyy | |
01/6/2020 10:07 | According to SNG's website Lansdowne has approx 17m shares. I did a rough calculation of 'sell' trades during the month of May, and it comes to around 30m shares. Now comes the guesswork. If you reckon that half of the total is Lansdowne selling, then they must be nearly out. My sense is that, at best they have all but sold down. At worst, another 2 or 3 weeks say. This is only a guestimate guys. | ramridge | |
01/6/2020 09:59 | Seller/s happy to make less and less profit. | wetdream | |
01/6/2020 09:58 | Well hope you do. We can both make from both sides really. | spartan attack | |
01/6/2020 09:55 | SA - I dont know whether COPD wil work or ongoing work related to COVID will be successful or not But thing I know in next few days I'll get price of 50P+ easily and hence good share to ride now | idontflykathyy | |
01/6/2020 09:50 | Bought more today at 43P SA - what the hell you are doing here ? Come back to Metro board... leave this guys here. SNG spent a decade on COPD trial and now read out in few days so expect a massive spike sometime in mid june and you will look stupid lol | idontflykathyy | |
01/6/2020 09:50 | Very positive. | sainvestor | |
01/6/2020 09:47 | Interesting article in medRxiv on Thursday reporting on a trial using injected Interferon beta (IFN). medRxiv is a medical archive that publishes preprints of medical research before peer review. SNG's nebulized treatment should have higher efficacy than injected treatments. Conclusion was this: The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively) .....significantly increased discharge rate on day 14 and decreased 28-day mortality Bottom line - IFN works for significantly improved outcomes. Report is here hxxps://www.medrxiv. | asteria1 | |
01/6/2020 09:20 | https://www.trialsit | sainvestor | |
01/6/2020 09:00 | What the theory on no update on positions? | sainvestor | |
01/6/2020 08:46 | Afraid we ain’t going anywhere much while the insti/s is/are off loading imho | judijudi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions